ViroMissile Unveils IDOV™ Platform: A Potential One-Shot Cure for Cancer

SAN DIEGO, May 7, 2025 /PRNewswire/ -- ViroMissile was recognized by "Life Sciences Review" magazine as the Top Cancer Destroying Platform 2025. A pioneering biotech firm headquartered in San Diego, ViroMissile is transforming the landscape of cancer treatment with its Intravenously Deliverable Oncolytic Virus (IDOV™) platform. This innovative approach aims to provide a universal, single-dose therapy capable of targeting and eliminating various cancer types.

At the core of ViroMissile's breakthrough is a genetically engineered vaccinia virus designed to selectively infect and destroy cancer cells while simultaneously activating the body's immune response. Unlike traditional oncolytic viruses that require direct tumor injections, the IDOV™ platform enables systemic intravenous delivery, allowing the therapeutic virus to reach tumors throughout the body.

"Our goal is to develop a broadly applicable therapy that leverages the immune system to combat cancer," said Dr. Nanhai George Chen, CEO of ViroMissile. "By focusing on fundamental characteristics of cancer cells, such as rapid division, we aim to create a treatment effective across multiple cancer types."

Since launching its operations in 2018, ViroMissile has made significant strides in developing its third-generation oncolytic viruses. Pre-clinical studies in mouse models have demonstrated that a single injection can eradicate multiple cancers. Early clinical trials in China have provided compelling evidence that the virus successfully reaches tumors in human patients. The next round of clinical trials will take place in the United States and Australia.

The IDOV™ platform includes several product candidates:

• IDOV-Safe™: Engineered for enhanced safety profiles.
• IDOV-Immune™: Designed to boost immune system activation.
• IDOV-Stealth™: Optimized to evade immune detection for improved delivery.
• IDOV-Anti-Angio™: Targets tumor blood vessel formation to inhibit growth.

ViroMissile's approach addresses a critical challenge in oncology: delivering effective therapies with minimal invasiveness and maximum efficiency. By enabling intravenous administration, the company aims to overcome limitations associated with localized treatments, potentially offering a more patient-friendly alternative.

The company's lean operational model, combined with strategic investments, has facilitated rapid progress without excessive overhead. This efficiency positions ViroMissile to bring its innovative therapies to market swiftly, addressing unmet needs in cancer treatment.

As ViroMissile continues to advance its clinical programs, the company is actively seeking partnerships and investment to support further development and commercialization efforts. With its promising platform, ViroMissile stands at the forefront of a new era in cancer therapy.

For more information, please visit www.viromissile.com.

Contact: 
Derek Danziger, APR
619-200-2145 cell
[email protected]

SOURCE ViroMissile